Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
No open-market purchase by an insider of LivaNova was filed in the last 90 days. The latest on record was on Nov 10, 2021.
How often do LivaNova insiders buy and sell shares?
Since 2015, LivaNova insiders reported 4 open-market purchases and 127 sales on Forms 4 and 5, with purchases in 4 different years, most recently 2021.
Who is selling LivaNova stock?
In the last 90 days, 3 insiders of LivaNova (LIVN) reported 4 open-market sales worth $819K in total on SEC Form 4. The largest seller by value was Francesco Bianchi, with $405K. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Do members of Congress trade LIVN?
No trade in LivaNova (LIVN) was disclosed by a member of Congress in the last 12 months.
When does LivaNova report its next results?
LivaNova's next results are expected on Feb 23, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
+69.8% (+$37.31) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $53.42 on Nov 20, 2025 to $90.73 on Nov 20, 2026 (+69.8%). Disclosed in this range: 6 insider trades, 1 pre-arranged insider sale, 0 Congress trades, and 15 13F position changes for 3 quarters ending in it.
$50$60$70$80$100$90.73
DecJan 2026FebMarAprMayJunJulAugSepOctNov
13F holdings, by quarter end
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Fund 13F reports are quarter-end snapshots filed up to 45 days later, so they are shown under the chart across the quarter they describe, not on the price line. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.Show the 7 trades in this range as a list
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Health Care Equipment company based in Houston, Texas.
Last 12 months
+69.8%
S&P 500 +5.7% over the same dates
Market value
$5B
Close of Nov 20, 2026 × shares outstanding (per ADS where it applies)
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 6.36M shares sold short (11.5% of shares outstanding), +2.6% vs the previous count, 12.4 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
New federal contracts from the last 12 months add up to 0.06% of that revenue. Contract money is usually earned over several years, so this is a size comparison, not a share of sales.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
When insiders usually buy
Last results
Nov 4, 2026
Within the 30 days after it, until Dec 4, 2026
Next results, expected
Feb 23, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
Not enough history
From LivaNova's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know LivaNova's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Since Nov 19, 2025, LIVN is up 68.3% and the index fund is up 4.1%: 64 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much LIVN moves
A usual day
±1.2%Half of the sessions moved less than this, half moved more.
Daily range (ATR 14)
3.7%How far the price usually travels in a session, the gap from the day before included. Wilder's 14-session average.
Largest one-day fall
−8.4%Aug 5, 2026
Largest one-day rise
+17.9%Nov 4, 2026
Deepest fall of the year
−18.9%From the close of Feb 26, 2026 to May 5, 2026.
Days of 5% or more
6Out of 252 sessions, in either direction.
Beta 1.0(1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 251 trading days (1 = in step with it).
Insider buying and selling since 2015
Insiders of LivaNova reported 4 open-market purchases and 127 sales since 2015; purchases in 4 different years, most recently 2021.
Year
Bought
Sold
2026
—
$1.26M7×7 trades
2025
—
$98K2×2 trades
2024
—
$3.54M4×4 trades
2023
—
$94K1×1 trade
2022
—
$677K6×6 trades
2021
$90K1×1 trade
$1.68M11×11 trades
2020
$47K1×1 trade
$144K2×2 trades
2019
$73K1×1 trade
$2.51M19×19 trades
2018
—
$6.13M31×31 trades
2017
$59K1×1 trade
$1.32M15×15 trades
2016
—
$54.6M27×27 trades
2015
—
$275K2×2 trades
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Insiders. In the 12 months to Nov 19, 2026, insiders of LivaNova filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 7 open-market sales (about $1.26M, in 7 filings, by 4 people). One Form 4 can list many transactions. In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 3 open-market sales (about $162K, in 3 filings). (LivaNova on OQRO)
Funds and stakes. Fund 13F filings recorded in the 12 months show 13 new or larger positions and 2 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings. 10 federal contract awards to the company were recorded in the 12 months, with about $818K obligated so far. A contract amount is what the agency obligated, not revenue. FINRA short interest for LIVN on the settlement date of Oct 30, 2026 was 6,362,366 shares (+2.63% on the previous report), about 12.42 days of average volume.
Company reports, price and press. LivaNova filed a Form 8-K on Nov 4, 2026 (Item 2.02) that OQRO classes as: reported its results. LivaNova filed a Form 8-K on Aug 5, 2026 (Item 2.02) that OQRO classes as: reported its results.
Who holds it. 302 funds reported a stake in LivaNova in their 13F for Q2 2026. The largest by value: BlackRock, Inc. (12.8% of the value reported), PRIMECAP MANAGEMENT CO/CA/ (7.0% of the value reported), FMR LLC (5.3% of the value reported).
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 12 months to Nov 19, 2026, insiders of LivaNova filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 7 open-market sales (about $1.26M, in 7 filings, by 4 people). One Form 4 can list many transactions.
In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 3 open-market sales (about $162K, in 3 filings).
The largest sale: Francesco Bianchi, Director, about $273K, filed Sep 14, 2026.
Funds and stakes
Fund 13F filings recorded in the 12 months show 13 new or larger positions and 2 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings
10 federal contract awards to the company were recorded in the 12 months, with about $818K obligated so far. A contract amount is what the agency obligated, not revenue.
FINRA short interest for LIVN on the settlement date of Oct 30, 2026 was 6,362,366 shares (+2.63% on the previous report), about 12.42 days of average volume.
In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew: Hood River Capital Management LLC (increased, 1,928,937 shares); Artisan Partners Limited Partnership (increased, 101,947 shares); the largest that shrank: Bailard, Inc. (sold out); Maverick Capital Ltd (sold out). A 13F is a quarter-end snapshot with no trade date.
For fiscal 2025, the company's proxy statement reported total compensation of $8.05M for its principal executive officer, and an average of $2.67M for the other named executive officers.
Company reports, price and press
LivaNova filed a Form 8-K on Nov 4, 2026 (Item 2.02) that OQRO classes as: reported its results.
LivaNova filed a Form 8-K on Aug 5, 2026 (Item 2.02) that OQRO classes as: reported its results.
LivaNova filed a Form 8-K on Jan 14, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member.
Press coverage listed by Finnhub: "LivaNova: Paying Off The Last Legacy Bill Just As The Sleep Apnea Market Opens Up" (SeekingAlpha, Nov 12, 2026).
Press coverage listed by Finnhub: "LivaNova PLC 2026 Q3 - Results - Earnings Call Presentation" (SeekingAlpha, Nov 6, 2026).
Press coverage listed by Finnhub: "LivaNova PLC Q3 2026 Earnings Call Summary" (Yahoo, Nov 4, 2026).
LIVN closed at $94.54 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $78.14 to $94.54, a change of +21.0%.
Who holds it
302 funds reported a stake in LivaNova in their 13F for Q2 2026. The largest by value: BlackRock, Inc. (12.8% of the value reported), PRIMECAP MANAGEMENT CO/CA/ (7.0% of the value reported), FMR LLC (5.3% of the value reported).
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 4, 2026.
Off-exchange trading: 44.7% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (30.0% on ATS, 14.7% with other brokers), above its 26-week average of 42.7%. Weeks of Sep 21 to Oct 16, 2026.
Week of Apr 20ATSOther off-exchangeFull height = all shares tradedWeek of Oct 12
Largest ATS: SIGMA X2 (13.2%), UBS ATS (11.2%), INTELLIGENT CROSS LLC (10.8%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Where the revenue comes from
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Feb 25, 2026. Read the filing
By business segment
Cardiopulmonary$785M57%
+15% on the year before ($684M). Operating income $108M, a 14% margin
Neuromodulation$593M43%
+7.0% on the year before ($554M). Operating income $215M, a 36% margin
Total revenue$1.39B+11%
The segments reach the total once $9.86M of items outside them is counted: corporate items, and the removal of sales between segments so they are not counted twice, as the company reports them.
By region
U.S. Pension Benefits$740M53%
+6.4% on the year before ($695M)
Rest of World$379M27%
+12% on the year before ($338M)
Europe$269M19%
+22% on the year before ($220M)
Total revenue$1.39B+11%
The company also reports United Kingdom ($55.9M), which group lines above and are not added again.
The year in the managers' words
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 6,000 words.
LivaNova has elected to omit certain discussions on the earliest of the three years covered in this Report. Refer to Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations located in LivaNova’s Annual Report on Form 10-K for the year ended December 31, 2024, filed on February 25, 2025, for reference to the discussion of 2023, the earliest of the three fiscal years presented.
What the section covers (14 headings)
Description of the Business
Macroeconomic Environment and Global Supply Chain
Cybersecurity Incident
Business Segments
DRE, DTD, and OSA
Results of Operations
Critical Accounting Estimates
New Accounting Pronouncements
Liquidity and Capital Resources
Operating Activities
Investing Activities
Financing Activities
Market and Credit Risk
Factors Affecting Future Operating Results and Share Price
Source: SEC EDGAR, Form 10-K filed Feb 25, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Risk factors in the annual report
Latest annual report filed Feb 25, 2026, compared with the one filed Feb 25, 2025. Read the filing
New risk factors in the latest annual report (4 headings)
Changes in global trade policies, including the imposition of tariffs, trade restrictions, export controls, sanctions, or other protectionist or retaliatory measures by the U.S. or other jurisdictions, may adversely affect LivaNova’s business, financial condition, and results of operations.
Failure to protect, maintain, or upgrade LivaNova’s IT systems or products, or safeguard against cybersecurity incidents, service disruptions, or data corruption could have a material adverse effect on LivaNova’s business, results of operations, financial condition and reputation.
The incorporation and use of AI technologies may present risks and challenges that could adversely affect LivaNova’s business, operations, and reputation.
Shareholder activism and increased investor engagement could divert management’s attention, disrupt the Company’s operations, and adversely affect the business and share price.
No longer listed (2 headings from the year before)
Cybersecurity incidents or other disruptions to LivaNova’s information technology systems could lead to reduced revenue, increased costs, liability claims, regulatory fines, litigation, harm to LivaNova’s competitive position, and loss of reputation.
LivaNova’s research and development efforts rely upon investments and investment collaborations, and the Company cannot guarantee that any previous or future investments or investment collaborations will be successful.
Legal proceedings (Item 3)
Information pertaining to certain material pending legal and regulatory proceedings and settlements is incorporated herein by reference to “Note 11. Commitments and Contingencies” in LivaNova’s consolidated financial statements and accompanying notes, beginning on page F-1 of this Report, and should be considered an integral part of “Part I, Item 3. Legal Proceedings” of this Report.
The company describes its cases in the notes to its financial statements, in the same filing.
Source: SEC EDGAR, Form 10-K filed Feb 25, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.